ISRCTN42412334已完成不适用
Phase II study: investigation of the safety and efficacy of a protocol for tight glycaemic control in patients with chronic obstructive pulmonary disease (COPD) exacerbations admitted to an acute medical unit
St George's, University of London (UK)0 个研究点目标入组 20 人开始时间: 2008年11月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Physician diagnosis of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) as primary cause for admission
- •2. Able to enter study within 24 hours of admission
- •3. Age greater than 40 years, male and female
排除标准
- •1. Intensive care unit admission
- •2. Moribund or not for active treatment
- •3. Admission expected to last less than 48 hours
- •4. Unable or unwilling to give informed consent
- •5. Known type I diabetes mellitus
- •6. Patients with reduced awareness of hypoglycaemia including reduced Glasgow Coma Scale or those taking beta blockers
- •6. Patients with renal or hepatic failure at increased risk of hypoglycaemia
研究者
相似试验
招募中
2 期
Phase II study to evaluate the safety and the efficacy of CBD (Bortezomib, Cyclophosphamide, Dexamethasone) regimen for the patients with relapsed and/or refractory multiple myelomarelapsed and/or refractory multiple myelomaJPRN-UMIN000003076ara Hospital Kinki University School Of Medicine20
尚未招募
2 期
A Phase II Study to Investigate the Safety and efficacy of APC201 for the Treatment of Pain Associated with Osteoarthritis of the KneeACTRN12623000273684Andros Pharmaceuticals Pty Ltd60
已完成
2 期
A clinical trial to study the safety and efficacy of a monoclonal antibody in patients with active psoriasisCTRI/2008/091/000296Biocon Limited
进行中（未招募）
2 期
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 in hand and foot skin reaction in Cancer Patients.CTRI/2023/01/048670OnQuality Pharmaceuticals (USA) LLC
尚未招募
2 期
Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR inhibitor-Associated HFSR in Cancer Patients.CTRI/2021/07/034694ONQUALITY PHARMACEUTICALS USA LLC